Stevens-Johnson Syndrome: Public Health and Genomic Insights - April 30, 2015

Genomics|Features|Stevens-Johnson Syndrome

Stevens-Johnson Syndrome

Stevens-Johnson Syndrome: Public Health and Genomic Insights - April 30, 2015

CDC investigates first Stevens-Johnson Syndrome outbreak in United States

What is Stevens-Johnson syndrome? From the Mayo Clinic

Family history is a risk factor for Stevens-Johnson syndrome, from the Mayo Clinic

Find out which genes have been reported in relation to Stevens-Johnson Syndrome, from the HuGE Navigator

Research directions in genetically-mediated Stevens-Johnson syndrome/toxic epidermal necrolysis, National Human Genome Research Institute Meeting Presentations, March 2015

HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese.
Yang F et al. Pharmacogenomics J. 2015 Apr 28.

Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases.
Davis RL et al. Pharmacoepidemiol Drug Saf 2015 Apr 24.

Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions.
Chen Z et al. Neurology 2014 Nov 25. (22) 2077-84

Personalized medicine approaches in epilepsy.
Walker LE et al. J. Intern. Med. 2015 Feb (2) 218-34

Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine.
Park HJ et al. Eur. J. Clin. Pharmacol. 2015 Jan (1) 35-41

HLA-B*15:02 association with carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in an Indian population: a pooled-data analysis and meta-analysis.
Khor AHP et al. Epilepsia 2014 Nov (11) e120-4

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.
Caudle KE et al. Clin. Pharmacol. Ther. 2014 Nov (5) 542-8

Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Chung WH et al. JAMA 2014 Aug 6. (5) 525-34

Epidemiology of severe drug hypersensitivity.
Dodiuk-Gad RP et al. Semin Cutan Med Surg 2014 Mar (1) 2-9

Genetic predictors of Stevens-Johnson syndrome and toxic epidermal necrolysis induced by aromatic antiepileptic drugs among the Chinese Han population.
Wang W et al. Epilepsy Behav 2014 Aug 16-9

Identification of risk factors for carbamazepine-induced serious mucocutaneous adverse reactions: A case-control study using data from spontaneous adverse drug reaction reports.
Bertulyte I et al. J Pharmacol Pharmacother 2014 Apr (2) 100-38

Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai population.
Saokaew S et al. PLoS ONE 2014 (4) e94294

Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U et al. Epilepsia 2014 Apr (4) 496-506

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
Drozda K et al. Pharmacotherapy 2014 Feb (2) 166-84

Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study.
Toh DSL et al. Pharmacogenomics J. 2014 Aug (4) 316-21

Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China.
He XJ et al. Pharmacol Rep 2013 (5) 1256-62

HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.
Yeo SI et al. Int J Rheum Dis 2013 Jun (3) 254-7

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Rattanavipapong W et al. Epilepsia 2013 Sep (9) 1628-38